Skindex, a Quality-of-Life Measure for Patients with Skin Disease: Reliability, Validity, and Responsiveness

Chren, Mary‐Margaret; Lasek, Raymond J.; Quinn, Linda; Mostow, Eliot N.; Zyzanski, Stephen J.

doi:10.1111/1523-1747.ep12365600

Cited by 639 publications

(573 citation statements)

References 38 publications

Supporting

Mentioning

531

Contrasting

Unclassified

Order By: Relevance

“…For example, the nature of these effects, their relationship with each other and to clinical variable. 3 The concept of health-related quality of life is gradually expanding in both scope and importance in medical care. Basically, it consists of a constellation of information about an individual's physical, social and psychological well-being.…”

Section: Introductionmentioning

confidence: 99%

Assessment of prescribing pattern and quality of life of dermatology patients by using dermatology quality life index

Sangeetha¹,

Raghu²,

Nataraj³

et al. 2017

Int J Res Dermatol

View full text Add to dashboard Cite

Background: The goal of the study was to assess the prescribing pattern, pattern of skin diseases among the patients and to assess the impact of quality of life in various Skin diseases of dermatological patients by using dermatological quality life index (DLQI). The present study aims at improving the patient’s knowledge towards their disease and medication and also to measure the improvement of Quality of life of patients.Methods: A prospective observational study was carried out for a period of six months at Department of Dermatology Basaveshwara Medical College and Hospital, Chitradurga.Results: Total 150 patients are included. 58 was males and 92 were females. The most skin disease is seen in the age group of 21-40 (40.7%). Majorly skin disease are seen in the illiterate people is (62%), (70.7%) married and 15.3% of socio-economic status of the patients. The major skin disease are seen in the study are psoriasis (12.66%), scabies (16.66%), dermatitis (9.33) and followed by urticaria (6.66%), eczema (4.66%), acne (5.33%). Anti-histamines (16.6%), emollients (9.33%), corticosteroids (9.33%), anti puritics (6.66%), kerotolyte (6.66%) are majorly prescribed drugs. The study showed that there was an extremely significant improvement in DLQI of patients in comparison with first visit result and follow up visit. Whose P value is (<0.001) extremely significant. Conclusions: Therefore the pharmacist patient education found to have significant influence on improves the patient knowledge towards their disease and medication which shows the positive impact on quality of life among the patients of skin diseases.

show abstract

Section: Introductionmentioning

confidence: 99%

Assessment of prescribing pattern and quality of life of dermatology patients by using dermatology quality life index

Sangeetha¹,

Raghu²,

Nataraj³

et al. 2017

Int J Res Dermatol

View full text Add to dashboard Cite

show abstract

“…The determination of PASI is labour intensive however, that is why other endpoints have been used in clinical trials, such as Overall Lesion Severity Scale (OLS) and Physician Global Assessment (PGA). Validated patient reported outcomes include Dermatology Life Quality Index (DLQI), visual analogue scale for the judgement of pruritis (VAS), Skindex-29 and the Psoriasis Symptom Assessment (PSA) [15][16][17]. A combined endpoint of effects on the skin, (PASI), joints (ACR) and quality of life (Euro EQ-50) has been proposed as well [18].…”

Section: Efficacymentioning

confidence: 99%

Biologicals in the Treatment of Plaque Psoriasis: Drug Selection by Means of the SOJA Method

Janknegt¹

2016

J Pharma Care Health Sys

View full text Add to dashboard Cite

The treatment of plaque psoriasis is changing because of the introduction of new treatment options. The goal of this article is to allow a transparent and rational choice of medicines by means of the System of Objectified Judgement Analysis. The following selection criteria (relative weight) were applied: approved indications (40), drug interactions (60), clinical efficacy (400), safety (300), dosage frequency (100) and documentation (100). Acquisition cost was not taken into consideration to allow a preselection on quality aspects only. Adalimumab, etanercept, infliximab and ustekinumab were compared on these criteria. Infliximab and ustekinumab showed the highest scores and are the most suitable medicines for the treatment of severe plaque psoriasis. Of course, cost will play a key role in the final selection in individual hospitals. Weight Approved indications 40 Drug Interactions 60Clinical efficacy 400Safety 300Dosage frequency 100 Documentation 100Total 1000 Selection Criteria Approved IndicationsThe number of licensed indications is a good measure of the applicability and documentation of the drugs. Although this analysis is limited to the treatment of plaque psoriasis, the fact that a drug is approved for (almost) all indications listed below is, from a formulary point of view, advantageous to another drug, which is approved for only one or two applications.The percentage of the maximum score for approved indications was obtained as follows (Table 2): IndicationMaximum Score (%)Plaque psoriasis 50% Psoriatric arthritis 20%Rheumatoid arthritis 10% Spondylitis ankylopoetica 10%Inflammatory bowel disease 10% Drug interactionsInteractions play a role only in patients who use other drugs which may interact with biologicals. However, it is a relevant criterion from a formulary point of view.The score for each drug was dependent on the frequency and severity of observed drug interactions. Clinical efficacyClinical efficacy is always a very important selection criterion for any group of drugs. The score for each drug was derived from the results of double-blind comparative studies. SafetyThe extent and the severity of adverse effects is another important selection criterion for drugs. A distinction was made between "minor" side effects, such as gastrointestinal disturbances or skin reactions, occurring in clinical trials and severe or even life-threatening adverse reactions observed with large scale use of the drugs. The evaluation of the "minor" adverse effects was based on results of double blind comparative clinical studies.

show abstract

“…Patient‐reported outcome (PRO) instruments have been developed to meet this need, but they did not satisfy product‐labelling regulatory requirements and claims and were not designed to be used exclusively by individuals with psoriasis 6, 7. More recent instruments have been proprietary and/or limited in scope of evaluation 8, 9.…”

Section: Introductionmentioning

confidence: 99%

Patient‐reported symptoms and signs of moderate‐to‐severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial

Papp

Blauvelt

Kimball

et al. 2018

Acad Dermatol Venereol

View full text Add to dashboard Cite

BackgroundHow patients experience the symptoms/signs of psoriasis is highly relevant for assessing treatment response.ObjectivesCompare outcomes with guselkumab, placebo and adalimumab utilizing the novel, validated Psoriasis Symptoms and Signs Diary (PSSD).Methods VOYAGE 1 is an ongoing, phase III, double‐blinded, controlled trial of patients with moderate‐to‐severe psoriasis. Patients were randomized to guselkumab 100 mg every 8 weeks; placebo‐to‐guselkumab 100 mg every 8 weeks; or adalimumab 40 mg every 2 weeks. The PSSD was self‐administered to assess symptoms (i.e. itch, skin tightness, burning, stinging and pain) and signs (i.e. dryness, cracking, scaling, shedding/flaking, redness and bleeding) of psoriasis (0–10 [absent‐to‐worst‐imaginable]) every 24 h. Symptom and sign summary scores were derived (0–100) based on average scores of the individual symptoms and signs. Proportions of patients with clinically meaningful improvements and symptom‐ and sign‐free scores of 0 were evaluated across treatment groups at weeks 16, 24 and 48.ResultsAt baseline, 652 of 837 randomized patients had PSSD scores. The proportion of patients achieving clinically meaningful improvements in PSSD summary scores was significantly higher in the guselkumab group compared with the placebo group at week 16 (P < 0.001) and compared with the adalimumab group at weeks 24 (P = 0.002) and 48 (P < 0.001). The proportions of patients achieving PSSD symptom and sign summary scores of 0 (i.e. symptom‐ and sign‐free) were significantly higher for guselkumab vs. placebo at week 16 and vs. adalimumab at weeks 24 and 48 (all P < 0.001).ConclusionsBased on PSSD scores, greater improvements in symptoms and signs of psoriasis were reported by patients treated with guselkumab compared with placebo at week 16 or adalimumab through 48 weeks.

show abstract

Skindex, a Quality-of-Life Measure for Patients with Skin Disease: Reliability, Validity, and Responsiveness

Cited by 639 publications

References 38 publications

Assessment of prescribing pattern and quality of life of dermatology patients by using dermatology quality life index

Assessment of prescribing pattern and quality of life of dermatology patients by using dermatology quality life index

Biologicals in the Treatment of Plaque Psoriasis: Drug Selection by Means of the SOJA Method

Patient‐reported symptoms and signs of moderate‐to‐severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial

Contact Info

Product

Resources

About